| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 35,442 | 26,793 | ||
| Other current assets | 145 | 214 | ||
| Total current assets | 35,587 | 27,007 | ||
| Total assets | 35,587 | 27,007 | ||
| Accounts payables | 6,439 | 4,977 | ||
| Payable offering costs | 75 | 75 | ||
| Accrued liabilities | 65 | 2 | ||
| Employee compensation and benefits | 4,998 | 5,081 | ||
| Total current liabilities | 11,577 | 10,135 | ||
| Total liabilities | 11,577 | 10,135 | ||
| Additional paid in capital | 116,383 | 101,783 | ||
| Accumulated deficit | -92,373 | -84,911 | ||
| Total shareholders' equity | 24,010 | 16,872 | ||
| Total liabilities and shareholders' equity | 35,587 | 27,007 | ||
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)